Headquartered in Seattle, WA Fiscal year ends December NASDAQ: ATOS atossatherapeutics.com
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The company's lead and sole product candidate, (Z)-endoxifen, is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. (Z)-endoxifen is being evaluated in oncology, specifically ER-positive breast cancer via the EVANGELINE Phase 2 study, and in rare diseases including Duchenne Muscular Dystrophy and McCune-Albright Syndrome. The company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa holds Orphan Drug Designation and Rare Pediatric Disease designation from the FDA for (Z)-endoxifen in DMD, as well as RPD designation for McCune-Albright Syndrome. Upon approval, drugs with RPD designation may be eligible for a Priority Review Voucher, which can be sold or transferred. The company is pre-revenue and funds operations through equity offerings. Its pipeline is supported by a growing global intellectual property portfolio including multiple recently issued U.S. patents. Updated
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need.
The Wall Street consensus 12-month price target for ATOS is $19.00.
